BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

...Gall was SVP of corporate development at Sarepta Therapeutics Inc. (NASDAQ:SRPT); McGrath was CSO of Complix N.V....
BioCentury | Nov 27, 2018
Distillery Therapeutics

Cancer

...MM. AstraZeneca plc has AZD5991, an MCL1 inhibitor, in Phase I testing for hematologic malignancies. Complix N.V....
BioCentury | Feb 21, 2018
Distillery Therapeutics

Cancer

...Inc. has AMG 176, a MCL1 inhibitor, in Phase I testing for multiple myeloma (MM). Complix N.V....
BioCentury | Jan 31, 2018
Distillery Therapeutics

Cancer

...AMG 176, an MCL1 inhibitor, in Phase I testing to treat relapsed or refractory MM. Complix N.V....
BioCentury | Oct 12, 2017
Product R&D

Artificial mini proteins

...FOG Pharmaceuticals Inc. and Aileron Therapeutics Inc. are developing stapled α-helical peptides for cancer and Complix N.V....
...peptide inhibitors, antibodies, or vaccines. Companies and Institutions Mentioned Aileron Therapeutics Inc. (NASDAQ:ALRN), Cambridge, Mass. Complix N.V....
BioCentury | Aug 22, 2017
Distillery Therapeutics

Cancer

...a MCL1 inhibitor, in Phase I testing to treat relapsed or refractory multiple myeloma (MM). Complix N.V....
BioCentury | Jun 15, 2017
Tools & Techniques

Breaking the barrier

...Co. Inc. became the first pharma to disclose a play in the field, partnering with Complix N.V....
...class. I think biologicals for intracellular targets will be one of those new fields,” said Complix...
...transport (A) , or to directly transport the cargo across the cell membrane (B) . Complix N.V....
BioCentury | Sep 22, 2016
Distillery Therapeutics

Therapeutics: Myeloid leukemia cell differentiation protein (MCL1); eukaryotic translation initiation factor 4B (EIF4B)

...AMG 176 , a MCL1 inhibitor, in Phase I testing to treat multiple myeloma (MM). Complix N.V....
BioCentury | Jan 11, 2016
Company News

Merck, Complix deal

...partnered with Merck to discover and develop cancer treatments using Complix’s Cell-Penetrating Alphabodies (CPABs) technology. Complix...
...will have an option to receive exclusive, worldwide rights to compounds generated under the deal. Complix...
...declined to provide further details or financial terms. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Complix N.V....
BioCentury | Jan 7, 2016
Company News

Merck, Complix in cancer discovery deal

...Inc. (NYSE:MRK) to develop Cell-Penetrating Alphabodies (CPABs) against up to two undisclosed intracellular cancer targets. Complix...
...payment and milestones, plus tiered royalties. Merck declined to discuss details of the deal, and Complix...
...to an inquiry. CPABs are small proteins capable of binding to intracellular targets. According to Complix...
Items per page:
1 - 10 of 22
BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

...Gall was SVP of corporate development at Sarepta Therapeutics Inc. (NASDAQ:SRPT); McGrath was CSO of Complix N.V....
BioCentury | Nov 27, 2018
Distillery Therapeutics

Cancer

...MM. AstraZeneca plc has AZD5991, an MCL1 inhibitor, in Phase I testing for hematologic malignancies. Complix N.V....
BioCentury | Feb 21, 2018
Distillery Therapeutics

Cancer

...Inc. has AMG 176, a MCL1 inhibitor, in Phase I testing for multiple myeloma (MM). Complix N.V....
BioCentury | Jan 31, 2018
Distillery Therapeutics

Cancer

...AMG 176, an MCL1 inhibitor, in Phase I testing to treat relapsed or refractory MM. Complix N.V....
BioCentury | Oct 12, 2017
Product R&D

Artificial mini proteins

...FOG Pharmaceuticals Inc. and Aileron Therapeutics Inc. are developing stapled α-helical peptides for cancer and Complix N.V....
...peptide inhibitors, antibodies, or vaccines. Companies and Institutions Mentioned Aileron Therapeutics Inc. (NASDAQ:ALRN), Cambridge, Mass. Complix N.V....
BioCentury | Aug 22, 2017
Distillery Therapeutics

Cancer

...a MCL1 inhibitor, in Phase I testing to treat relapsed or refractory multiple myeloma (MM). Complix N.V....
BioCentury | Jun 15, 2017
Tools & Techniques

Breaking the barrier

...Co. Inc. became the first pharma to disclose a play in the field, partnering with Complix N.V....
...class. I think biologicals for intracellular targets will be one of those new fields,” said Complix...
...transport (A) , or to directly transport the cargo across the cell membrane (B) . Complix N.V....
BioCentury | Sep 22, 2016
Distillery Therapeutics

Therapeutics: Myeloid leukemia cell differentiation protein (MCL1); eukaryotic translation initiation factor 4B (EIF4B)

...AMG 176 , a MCL1 inhibitor, in Phase I testing to treat multiple myeloma (MM). Complix N.V....
BioCentury | Jan 11, 2016
Company News

Merck, Complix deal

...partnered with Merck to discover and develop cancer treatments using Complix’s Cell-Penetrating Alphabodies (CPABs) technology. Complix...
...will have an option to receive exclusive, worldwide rights to compounds generated under the deal. Complix...
...declined to provide further details or financial terms. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Complix N.V....
BioCentury | Jan 7, 2016
Company News

Merck, Complix in cancer discovery deal

...Inc. (NYSE:MRK) to develop Cell-Penetrating Alphabodies (CPABs) against up to two undisclosed intracellular cancer targets. Complix...
...payment and milestones, plus tiered royalties. Merck declined to discuss details of the deal, and Complix...
...to an inquiry. CPABs are small proteins capable of binding to intracellular targets. According to Complix...
Items per page:
1 - 10 of 22